Isconova releases Matrix M human PanFluVac trial data
In the phase I clinical study, comprising a total of 60 healthy volunteers, Matrix M demonstrated positive results. The study was conducted at The Gade Institute, University of
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.